| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.006 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.007 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.097 | 0.008 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.39 | 0.01 |